Rational modulation of the immune response with biologics represents one of the most promising and active areas for the realization of new therapeutic strategies. In particular, the use of function blocking monoclonal antibodies targeting checkpoint inhibitors such as CTLA-4 and PD-1 have proven to be highly effective for the systemic activation of the human immune system to treat a wide range of cancers. Ipilimumab is a fully human antibody targeting CTLA-4 that received FDA approval for the treatment of metastatic melanoma in 2011. Ipilimumab is the first-in-class immunotherapeutic for blockade of CTLA-4 and significantly benefits overall survival of patients with metastatic melanoma. Understanding the chemical and physical determinants recognized by these mAbs provides direct insight into the mechanisms of pathway blockade, the organization of the antigen-antibody complexes at the cell surface, and opportunities to further engineer affinity and selectivity. Here, we report the 3.0 Å resolution X-ray crystal structure of the complex formed by ipilimumab with its human CTLA-4 target. This structure reveals that ipilimumab contacts the front β-sheet of CTLA-4 and intersects with the CTLA-4:Β7 recognition surface, indicating that direct steric overlap between ipilimumab and the B7 ligands is a major mechanistic contributor to ipilimumab function. The crystallographically observed binding interface was confirmed by a comprehensive cell-based binding assay against a library of CTLA-4 mutants and by direct biochemical approaches. This structure also highlights determinants responsible for the selectivity exhibited by ipilimumab toward CTLA-4 relative to the homologous and functionally related CD28.
A ctivation of the immune system to target and eliminate malignancies is recognized as one of the most promising directions for cancer therapy (1) (2) (3) (4) . Two broad strategies for immunotherapy may be envisaged: inhibition of negative regulators of immune responsiveness (collectively known as checkpoint blockade) (2, (5) (6) (7) (8) and activation of costimulatory pathways (8) . A powerful example is provided by antibodies targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a T-cell surface molecule, which like the homologous CD28 (∼30% sequence identity) binds the B7-1 and B7-2 ligands (9) . While CD28 is constitutively expressed and is required, in conjunction with TCR engagement, for T-cell activation, CTLA-4 is a negative regulator of T-cell function expressed after T-cell activation to terminate the response. Ipilimumab, a fully human antibody targeting CTLA-4 (marketed as Yervoy), demonstrated improved overall survival in two phase-III clinical trials of metastatic melanoma (10, 11) and received FDA approval for the treatment of metastatic melanoma in 2011. Ipilimumab is the first-in-class immunotherapeutic for blockade of CTLA-4 and significantly benefits overall survival of patients with metastatic melanoma. Notably, combination therapies involving ipilimumab and other immunomodulators/checkpoint antibodies, such as those targeting PD-1 or tremelimumab (anti-CTLA-4) and anti-PD-L1, can result in enhanced activity (12) (13) (14) (15) .
Multiple mechanisms have been described for CTLA-4 function. These include negative signals from intrinsic effects of CTLA-4 expressed on activated T effector cells as a result of ligand binding. Extrinsic effects of CTLA-4 are the consequence of the ability of CTLA-4 expressed on Tregs to remove B7 ligands from the surface of dendritic cells or antigen presenting cells, resulting in significantly reduced suppression (16) . This regulatory mechanism of transendocytosis may also be operative in activated T effector cells (17, 18) . CTLA-4-B7 interactions also have intrinsic effects on Treg, dampening their proliferation or activation (19) .
Antibodies to CTLA-4 also operate through multiple mechanisms. Recent studies in murine models suggest that antibodies targeting CTLA-4 delete intratumoral Treg cells through an Fcγ receptor (FcγR)-dependent process (20, 21) . Although Treg depletion does not require ligand blocking, ample evidence indicates that inhibition of ligand binding to CTLA-4 is an important factor contributing to the antitumor activity of anti-CTLA-4 antibodies in murine models as well as in humans. These data include the demonstration in murine models that targeting of the effector T-cell compartment contributes to the antitumor activity of anti-CTLA-4, whereas exclusive targeting of the Treg cell compartment failed to elicit tumor protection-thus highlighting the importance of Significance Biologics represent a major class of therapeutics for the treatment of malignancies, autoimmune diseases, and infectious diseases. Ipilimumab is the first-in-class immunotherapeutic for blockade of CTLA-4 and significantly benefits overall survival of patients with metastatic melanoma. The X-ray crystal structure of the ipilimumab:CTLA-4 complex defines the atomic interactions responsible for affinity and selectivity and demonstrates that the therapeutic action of ipilimumab is due to direct steric competition with the B7 ligands for binding to both modalities for antitumor activity (6) . Blockade of CTLA-4 also promotes Treg suppression in vitro (6, 19) .
Human clinical studies with tremelimumab, which, like ipilimumab, blocks the interactions of CTLA-4 with its ligands, demonstrate that this antibody also has antitumor activity in addition to inducing adverse events (22) . Moreover, long-term survival of melanoma patients treated with either ipilimumab (23) or tremelimumab have been reported (24) . Notably, tremelimumab harbors the IgG2 isotype and thus cannot engage FcγRs, supporting a mechanism of action that relies largely on competitive inhibition with the B7 ligands (ref. 20 and references therein). In contrast, ipilimumab is an IgG1 that can engage human FcγR; consistent with this behavior, ipilimumab was shown to mediate antibody-dependent cell-mediated cytotoxicity (ADCC)-facilitated depletion of Treg cells in vitro (25) . However, only small numbers of patients have been analyzed for depletion of Treg at the tumor site by ipilimumab (26, 27) . Of note, FcγR polymorphisms have no impact on the survival of ipilimumab-treated patients (28) . Importantly, all aspects of ipilimumab-mediated CTLA-4 blockade require specific and high-affinity recognition of CTLA-4.
CTLA-4 and CD28 are type-I integral membrane proteins composed of a single Ig variable domain (IgV), a transmembrane segment, and a cytoplasmic tail bearing various signaling motifs. The IgV ectodomains share ∼30% sequence identity and exhibit a two-layered beta sheet involving the A′GFCC′C′′ strands of the front sheet and the ABED strands of the back sheet. Both molecules exist as covalent homodimers due to a disulfide bond formed between cysteines in the stalk segments connecting the IgV and transmembrane domains. A wide range of structural and biochemical data demonstrate that, despite this modest sequence similarity, both CTLA-4 and CD28 use the stereochemical features of a shared proline-rich motif (MYPPPY), present in the loops joining the F and G β strands, to bind the B7-1 and B7-2 ligands (9) . An essential property of any CTLA-4 therapeutic antibody is the ability to specifically engage CTLA-4, while exhibiting little or no cross-reactivity with CD28. In the case of cancer immunotherapy, recognition of CD28 and inhibition of ligand binding could inhibit T-cell activation, which would oppose the desired therapeutic activity. To define the nature of the inhibitory mechanism and the specificity exhibited by ipilimumab for CTLA-4, we report the crystal structure of the complex formed by a Fab fragment of ipilimumab and human CTLA-4, as well as complementary biochemical studies that confirm the epitope recognized by ipilimumab. This work unambiguously defines the ipilimumab recognition surface on CTLA-4, which partly overlaps the B7 ligand binding surfaces, indicating that direct steric competition contributes to the function of ipilimumab. This work also highlights the determinants responsible for the highly selective binding to CTLA-4 and provides the foundation for structure-guided engineering of ipilimumab variants with new in vitro activities (e.g., altered affinities for CTLA-4 and Fc receptors) for the realization of enhanced in vivo therapeutic functions.
Results and Discussion
Overall Structure of the Human CTLA-4:Ipilimumab Complex. The structure of the complex between monomeric human CTLA-4 (residues 1-118) and the Fab fragment derived from ipilimumab was determined and refined to a resolution of 3.0 Å, with R work and R free of 20.3% and 26.8%, respectively (Fig. 1A, Fig. S1A , and Table 1 ). The two independent copies of the complex in the asymmetric unit exhibit similar overall organization and superpose with a C α -root-mean-square deviation (C α -rmsd) of 0.74 Å, calculated over all experimentally defined C α atoms of CTLA-4 (2-116) and the V H (2-118) and V L (2-108) domains of the ipilimumab Fab fragment ( Fig. S1 ; the C α -rmsd is 1.24 Å when the constant domains of the Fab are included). The C α -rmsd between the two molecules of CTLA-4 in the asymmetric unit is 0.65 Å. The ipilimumab Fab exhibited typical CDR structural parameters, with elbow angles for the two independent molecules in the asymmetric unit of 168°and 170°. Due to the similarity of the two complexes, the discussion below refers to one of the CTLA-4:Fab complexes in the asymmetric unit ( Fig. 1 and Fig. S1B ), denoted L for light chain, H for heavy chain, and C for CTLA-4.
The binding interface is formed by residues from the C, C′, F, and G strands ( Fig. 1 B and C) of the front β-sheet of CTLA-4 and light chain complementarity determining regions 1 and 3 (LCDR1 and LCDR3) and heavy chain CDRs 1, 2, and 3 (HCDR1, HCDR2, and HCDR3) (Fig. 1) ) as well as 33 Glu, 35 Arg, and 39 Leu from the C strand and 46 Val from the C′ strand form an extended interface with residues from HCDR2 ( 52 Ser, 53 Fig. 2A) . The G strand from CTLA-4 is positioned along the cleft formed between the V L (LCDR1 and LCDR3) and V H (HCDR1 and HCDR2) domains ( Fig. 2 A and B) , whereas the adjacent F strand packs against HCDR1 and HCDR2 ( Fig. 2A ). Together these contacts account for almost all of the hydrogen bonding interactions within the complex.
101
Trp and
102
Leu from HCDR3 contact the center of the concave hydrophobic patch on the front face of CTLA-4 formed by 39 Leu, 46 Val, and 93 Ile, which extends the binding interface toward the CC′ loop located opposite the FG loop ( Fig. 2A) .
Overall, ∼13 hydrogen bonds and more than 90 contacts less than 4.0 Å contribute to the CTLA-4:ipilimumab Fab interface (Table S1 ). The total surface area buried at the binding interface is ∼1,880 Å An important consideration is that the species crystallized in these studies is monomeric CTLA-4, whereas the physiologically relevant cell surface receptor is a disulfide-linked homodimer involving Cys-122, which is outside the well-ordered globular domain and not included in the construct used in this crystallographic analysis. Structural and modeling analyses demonstrate that ipilimumab could readily accommodate the observed interactions within the bona fide CTLA-4 dimer. In particular, the unique mode of CTLA-4 dimerization, involving "side-to-side" contact between CLTA-4 monomers, places the FG loops distal to the dimer interface, such that the relevant epitope in each monomer is highly solvent accessible and appropriately positioned to recapitulate the interactions observed between the CTLA-4 monomer and the intact ipilimumab mAb (Fig. S2 ).
Cell-Based Evaluation of the CTLA-4:Ipilimumab Recognition Interface.
To confirm the crystallographically observed binding interface, we generated a library of 118 dimeric CTLA-4 mutants, which were transiently expressed in HEK293 cells and challenged with soluble ipilimumab. This approach provides a gold standard for evaluating extracellular interactions, as the members of the mutant library undergo all requisite co-and posttranslational modifications (e.g., correct disulfide bond formation and glycosylation) and are presented in the context of the mammalian cell surface environment (32) . In the context of cell surface expression, mutation of residues S20, R35, R40, Q76, D88, K95, E97, Y104, L106, and I108 of human CTLA-4 resulted in significant loss of ipilimumab binding ( Fig. 3 A and B and Fig. S3A ). Of the residues identified-R35, K95, E97, Y104, L106, and I108-are observed to make direct contacts with ipilimumab in the crystal structure. Residues R40 and D88 form a salt bridge that links two loops in the membrane proximal region of CTLA-4; disruption of this interaction likely causes local or global structural perturbations, resulting in loss of ipilimumab binding. Similarly, mutation of S20 or Q76 to aspartic acid also resulted in loss of ipilimumab binding, despite residing on the opposite side of CTLA-4 relative to the ligand-binding site. O-and N-linked glycosylation algorithms predict that S20 and N75 Parentheses indicate statistics for the high-resolution data bin for X-ray and refinement data. (adjacent to Q76) are potentially glycosylated, suggesting that mutations at residues 20 and 76 may affect installation or interaction with the carbohydrate moieties and potentially overall structural stability (Fig. S3B) (33) . The likelihood that mutations at these four residues (S20, R40, N75, and D88) cause global structural perturbation/destabilization of CTLA-4 is supported by the observation that they also result in the loss of binding to B7-1, B7-2, and ICOS-L, despite the observation that these residues reside outside of the experimentally determined binding interfaces ( Fig. 3 A and B and Fig. S3C ).
These mapping studies also highlight features of the binding surface recognized by B7-1, B7-2, and ICOS-L. A number of CTLA-4 mutations (R35A, R35D, K95A, K95D, E97A, E97R, Y104A, Y104D, I108A, and I108D) that strongly impair B7-1 and B7-2 binding are consistent with contacts observed in the CTLA-4:B7-1 and CTLA-4:B7-2 crystal structures (29, 30) (Fig.  S3C ). In addition, mutations at residues E33, E48, and Y100, also present at the CTLA-4:B7-2 binding interface, result in modest reductions in binding between CTLA-4 and B7-2. Again, mutations at residues R35, K95, E97, Y104, and I108 severely diminished ipilimumab binding, consistent with the direct steric blockade of CTLA-4 ligand binding by ipilimumab. This conclusion is further supported by results from a competition experiment demonstrating that ipilimumab, but not a control mAb, directly competes with hB7-1 for binding to beads coated with hCTLA-4 ( Fig. 4 A-C) . In addition, mutation of a number of CTLA-4 residues distal to the ligand-binding interfaces (e.g., V10, L12, S14, T69, T71, N78, Q82, G83, R85, A86, Y115, D118, and E120) exhibited impaired binding to B7-1, B7-2, and ICOS-L (Fig. S3D) . Importantly, all of the CTLA-4 mutants analyzed for binding showed similar mCherry expression (Fig. S3E) , making it unlikely that these mutations caused severe structural instability or protein misfolding. It is more likely that mutations of residues on CTLA-4 distal to the observed ligand binding site caused more subtle local structural perturbations. Three of these residues (Y115, D118, and E120) contribute to the CTLA-4 dimer interface, with the remaining residues arranged in a patch that extends toward the ligand binding surface (29, 30) . The mechanistic underpinnings for the binding properties of these mutants is not clear but may be related to the previous report that CTLA-4 lacking the interchain disulfide exists as an interconverting population of noncovalent dimer and monomer, which fully resolves to monomer when bound to B7-2 (34) Tyr, which lies outside the crystallographically observed binding interface, were mutated to alanine in dimeric human CTLA-4 containing the native interchain disulfide. Interactions between the wild-type and mutant dimeric CTLA-4 molecules and the Fab were examined by SEC (Figs. 5A and 6A) . The dimeric K95A and Y104A mutants did not exhibit any interaction with the Fab, whereas the dimeric M99A mutant exhibited significantly decreased association compared with the wild type (Fig. 6A) . The Y105A mutation did not significantly affect the interaction between dimeric CTLA-4 and the Fab, consistent with the placement of 105 Y outside the observed ipilimumab recognition interface (Fig. 6A) . The behavior of the wild-type dimeric CTLA-4 is consistent with the function blocking activity of intact ipilimumab.
The interactions between the Fab and the wild-type dimeric CTLA-4 and dimeric mutants were further evaluated by native nonreducing PAGE analysis. The ipilimumab Fab does not enter the gel under native PAGE conditions due to the overall positive charge of the Fab (pI of 8.8) at pH 8.0. Formation of the dimeric CTLA-4:Fab complex results in a species capable of entering the gel, whereas unbound dimeric CTLA-4 results in a distinct band (Fig. 5B) . As shown by the native PAGE results, the wild-type dimeric CTLA-4 interacted with Fab and formed new species consistent with the formation of the complex in the gel (Fig. 5B) . Dimeric K95A, M99A, and Y104A CTLA-4 mutants did not form any new species with ipilimumab Fab under native PAGE conditions (Fig. 6B) . Dimeric Y105A CTLA-4 productively interacted with the Fab , as demonstrated by the appearance of a new band in the native PAGE (Fig. 6B) . Importantly, as evidenced by fluorescence-monitored thermal denaturation, all of these dimeric CTLA-4 mutants are fully folded under the conditions used in these experiments (SI Materials and Methods and Fig. S4 ). These results are fully consistent with the observed Leu from the tip of the HCDR3 loop contacts the center of the CTLA-4 front face and interacts with a hydrophobic patch formed by 39 Leu, 46 Val, and 93 Ile. (B) Stick representation of the 99 MYPPPY 104 loop followed by G-strand residues (purple). The main-chain carbonyl and amide groups of the edge G-strand residues not involved in interstrand interactions with the F strand participate in hydrogen bonding interactions with LCDR3 (olive) and LCDR1 (teal) residues. Table S1 , it can be seen that residues from HCDR2 and HCDR3 interact with P1 and P2, respectively, whereas HCDR2, HCDR3, and LCDR3 interact with P3. Most of the interaction energy between CTLA-4:B7-1 and CTLA-4:B7-2 is derived from contacts with 99 MYPPPY 104 (9) , which is contained within the P3 segment recognized by ipilimumab, consistent with the function blocking activity of ipilimumab.
To understand the specificity of ipilimumab toward CTLA-4, linear peptides from both native and reduced human CD28-Fc fusion protein were generated, and their interactions with ipilimumab-coupled beads were examined. After elution from antibody-decorated beads, the mass and sequences of the bound peptides were characterized by MALDI-TOF MS and nano-liquid chromatography (nano-LC)-MS/MS, respectively. Of particular note is the CD28 tryptic peptide, 96 
IEVMYPPPYLDNEK

108
, which did not bind ipilimumab (Fig. S8) . In contrast, the corresponding peptide from CTLA-4, -containing epitope, which is consistent with the crystallographic data as discussed above (also see Table S1 ).
Mechanism of CTLA-4 Recognition and Blockade by Ipilimumab. The ability of CTLA-4 and CD28 to recognize both the B7-1 and B7-2 ligands is, in part, the consequence of the conserved FG loop (   99   MYPPPY   104 ) shared by both receptors (Fig. 7) . The introduction of mutations in this loop resulted in greater than 90% loss of affinity to the B7 ligands, identifying this segment as the core of the ligand binding surface on both CTLA-4 and CD28 (9) . Direct structural analyses of the CTLA-4:B7-1 and CTLA-4:B7-2 complexes (29, 30) showed that the 99 
MYPPPY
104 loop contributes ∼80% of the interfacial contacts with the B7 ligands. The three consecutive proline residues in the FG loop assume an unusual cis-trans-cis conformation, and with the exception of 99 Met, all of the main-chain carbonyl atoms are directed away from the ligand binding surface (Fig. 8A) . Given its chemical composition and conformation, this loop is devoid of free amide nitrogens or solventaccessible carbonyls (except for the terminal residues 99 M and 104 Y) and thus lacks determinants typically associated with directionality and specificity (i.e., hydrogen bond donors and acceptors). This unique and highly strained main-chain conformation provides significant geometric complementarity and hydrophobicity to support recognition of the concave surfaces presented by the front sheets of experiments for those CTLA-4 mutants that resulted in ≤50% binding to a particular query. (B) Residues at which mutations caused a significant loss of ipilimumab binding are mapped onto the CTLA-4 crystal structure. The residues highlighted in red make direct contact with ipilimumab, the two blue residues R40 and D88 form a salt bridge, and the two green residues (S20 and Q76) affected ipilimumab binding even though they are distal to the ipilimumab recognition surface. the B7 ligands. The structures of the unliganded murine and human CTLA-4 molecules demonstrate that this FG loop adopts essentially the same detailed conformation in both forms (35) , indicating that CTLA-4 presents a preformed B7-recognition surface. Although a structure of CD28 bound to a B-7 ligand is not available, the conserved sequences and conformation of the FG loop in the structure of a CD28:Fab complex (36), as well a series of mutagenesis experiments (9) , supports a mode of interaction with B7 ligands similar to that observed for CTLA-4.
Ipilimumab exploits the unique features of the FG loop and sandwiches the front sheet of CTLA-4 between LCDR1 and LCDR3 on one side and HCDR1 and HCDR2 on the other (Fig.  2A) . The region between LCDR3 and HCDR2 is rich in aromatic residues and stacks against the surface presented by the 99 MYPPPY 104 loop (Fig. 2B) . Residues in the tips of LCDR3 and LCDR1 are positioned proximal to the edge G-strand side of the front sheet of CTLA-4 and participate in a series of hydrogen bonding interactions with main-chain atoms of the G strand (Fig.  2B ). HCDR1 and HCDR2 stack almost perpendicular to the C, F, and G stands of CTLA-4 and provide both hydrophobic and hydrogen bonding interactions with the solvent-exposed residues on the F and C strands as well as those located toward the termini of the FG loop (Table S1 ). The HCDR3 loop contacts the center of the concave surface of CTLA-4 on its front sheet, with interactions extending toward the CC′ loop (Figs. 1A and 2A) . In the CTLA-4: B7 complexes, the tip of the FG loop (   99   MYPPPY   104 ) from CTLA-4 contacts the front face of the B7 ligands (Fig. 8 C and D and Fig.  S9 A and B) , with the CC′ loop of CTLA-4 positioned away from the B7 surface. However, in the CTLA-4:ipilimumab complex, the -
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− tip of the FG loop is only partially engaged, allowing for the association of the entire CTLA-4 front face with ipilimumab ( Fig. 8E and Fig. S9C ). In this way, the ipilimumab interaction surface not only sterically occludes the conserved 99 
MYPPPY
104 surface from availability to B7 ligands but also extends its interaction toward the opposite side of the CTLA-4 IgV domain (i.e., CC′ loop) (Fig. 8F) . The recognition of this extended CTLA-4 surface by ipilimumab (relative to the B7 ligands) is the consequence of the highly twisted architecture common to the front sheet of IgV domains of the antigen receptors, which results in the protrusion of the long FG and CC′ loops away from the plane of the front sheet, creating a concave surface on the CTLA-4 front sheet (Fig. 1C) (35) .
The differences in total buried surface area upon binding CTLA-4 (∼1,885 Å 2 for ipilimumab vs. ∼1,250 Å 2 for the B7 ligands), the greater number of hydrogen bonds (∼13 for ipilimumab vs. ∼5-7 for the B7 ligands), and the larger number of van der Waals contacts are consistent with the K d s exhibited by ipilimumab and B7 ligands for CTLA-4 (∼10 nM and ∼0.1-1 μM range, respectively) and the observation that ipilimumab competes effectively with the B7 ligands for binding CTLA-4. It is this direct competition between ipilimumab and the B-7 ligands that, in part, underlies the therapeutic efficacy of ipilimumab.
Ipilimumab Specificity. Although the B7 ligands interact with both CTLA-4 and CD28, the ability of ipilimumab to discriminate between these two functionally distinct receptors is critical for its therapeutic efficacy. CTLA-4 and CD28 share ∼30% sequence identity, including conservation of the critical core residues and disulfide linkages that are essential for maintaining the IgV domain fold. Overall, the structure of the Fab-bound human CTLA-4 monomer is similar to that in the apo-CTLA-4 homodimer structure (35) , the CTLA-4:B7-1 complex (30), the CTLA-4:B7-2 complex (29), and the CTLA-4:Lipocalin (37) complex, with C α -rmsds that range between 0.85 and 1.1 Å. Similarly, the C α -rmsds calculated with ipilimumab-bound human CTLA-4 against human CD28 (36) and murine CTLA-4 (38) ) are conserved among the structurally characterized CD28:CTLA-4 family members, including the sequences and the specific side-chain conformations; the sole exception is found in the apo-CTLA-4 homodimeric structure, where 100 Tyr adopts a different rotamer conformation to accommodate crystal contacts (35) . The conformation of this loop in the Fab-bound CD28 structure is also similar to that found in CTLA-4, including side-chain rotamers, with an overall Cα-rmsd of ∼0.3 Å (Fig. 8 A and B) . Based on these observations, these segments are not likely to be major determinants for the discrimination between CTLA-4 and CD28. Although many other CTLA-4 residues that interact with ipilimumab are conserved in CD28, there are a few important differences in sequence and conformation. Phe, respectively, and may contribute to the ability of ipilimumab to discriminate between CTLA-4 and CD28 (Fig. 8) .
As members of the antigen receptor group of the IgSF (35), both CTLA-4 and CD28 possess β bulges in C′ and G strands, which in CTLA-4 are centered on 48 
Glu and 110
Asn, respectively (in CD28, these bulges are centered on 46 
Asn, respectively) (Fig. 1B) (39) . The -Gly-X-Gly-sequence of G-strand β bulge observed in CTLA-4 is present in all V L domains and more than 98% of V H domains of mABs (39) . Notably, in CD28, the first glycine in this sequence is replaced by serine. In CD28, the single residue insertion 108 Glu (between the equivalent of 108
Gly and
109
Ile in CTLA-4), just before the G-strand β bulge, Fig. 7 . Sequence alignment of CTLA-4 and CD28. CTLA-4 residues interacting with ipilimumab are marked with blue triangles. The filled circles indicate residues from B7-1 (crimson) and B7-2 (purple) that make contacts less than 4.0 Å. Insertion in CD28, before the β bulge on the G strand, is shown with an arrow. Notice the sequence differences in the G-strand residues just after the 99 exaggerates the protrusion of the G strand (Figs. 1B, 7 , and 8B). In addition, on the G strand, immediately following the conserved 99 
MYPPPY
104 loop, all residues within the span of 105-109 are different in CD28 (Figs. 7 and 9 ). In particular, 107 Asn preceding the insertion is involved in two hydrogen bond interactions with the F-strand backbone, which further perturbs the canonical interstrand interaction between the F and G strands ( Fig. 9 B and C) , pushing the two strands farther apart than is typical. In CTLA-4, this region is involved in continuous main chain-main chain and main chain-side chain interactions with LCDR1 and LCDR3 (Fig. 2B) . Superposition of CD28 on the CTLA-4:ipilimumab complex predicts that the distortion of the G strand results in not only loss of hydrogen bonds but also a substantial steric clash with LCDR1 (Fig. 9C) . The detailed structural differences in the G strands of CTLA-4 and CD28 are likely the major determinants responsible for the specificity exhibited by ipilimumab. In addition, in CTLA-4 there is an insertion of residue 47 T just before the C′-strand β bulge (between the equivalent of residues 45 V and 46 E in CD28; Figs. 7 and 8A), which probably contributes to the differences in the CC′ loop conformation. However, this insertion is distal to the recognition interface and is not predicted to significantly impact the binding or selectivity.
An important consideration for normal physiology and therapeutic efficacy is that an optimal biological outcome is not always associated with the strongest achievable binding (i.e., very high affinity between receptor and ligand). This concept is illustrated by numerous physiological processes, such as the need for reversible binding interactions in oxygen delivery, replication, transcription, and translation, and these same principles are directly relevant to the development of therapeutic strategies (reviewed in ref. 40) . Notable examples are provided by recent reports of chimeric antigen receptor (CAR) T cells engineered to present scFv modules spanning a range of affinities for the target antigen (41, 42) . These studies demonstrate that scFvs with reduced affinities had increased selectivity for solid tumors, relative to normal cells, due to the requirement for higher surface density of target antigens to support productive engagement, a state often afforded by the targeted tumor cells. For example, CAR T cells bearing scFvs derived from nimotuxumab, but not cetuximab (43) , effectively discriminated between malignant cells and nonmalignant cells based on its ∼10-fold poorer K d for EGFR, which is expressed at significantly higher levels on the malignant cells (41) . Similar studies, which examined scFvs against EGFR (derived from the C10 anti-EGFR antibody) (44) and ErbB2 (derived from the 4D5 trastuzumab antibody) (45) with K d s spanning ∼2-3 orders of magnitude, have reinforced this concept. Together, these studies demonstrate that apparent K d s not only control selectivity between target and nontarget cells but can also impact CAR T-cell function (e.g., cytokine production) and suggest that on and off rates (i.e., k on and k off ) will have important mechanistic contributions to the ultimate therapeutic function. These examples and considerations underscore the need to achieve optimal, not maximal, affinities (and kinetics) to attain the desired biological/therapeutic activity. In the case of ipilimumab, affinity-attenuated variants could be generated, which would exhibit selectivity for activated Treg cells present at tumor sites due to their higher expression levels of CTLA-4, compared with other activated T cells (20, 21) . Additionally, it might be possible to engineer ipilimumab variants that are more responsive to the reduced pH often associated with the tumor microenvironment (46) (47) (48) . Thus, the structure of the CTLA-4:ipilimumab complex provides the foundation for the rationale design of affinity-modulated ipilimumab variants with distinct T-cell subset-targeting profiles and more selective and efficacious therapeutic properties.
Materials and Methods
Detailed methods can be found in SI Materials and Methods.
Monomeric and dimeric CTLA-4 and the monomeric IgV domain of hB7-2 were refolded as previously described from inclusion bodies (29, 49) . Ipilimumab Fab fragments were prepared by papain digestion. Crystals of the CTLA-4:ipilimumab Fab complex were obtained by sitting drop vapor diffusion and the structure determined by molecular replacement. The crystallographically determined binding interface was confirmed by a highthroughput FACS analysis using a library of CTLA-4 mutants expressed on the surface of HEK293 cells as well as by direct biochemical characterization of ipilimumab binding to wild-type CTLA-4 and mutant CTLA-4 variants.
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